HEM파마 Stock: price and insider trades · South Korea

HEM파마, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to DART (FSS). In the past year (18 October 2025 to 18 October 2026), 19 filings came from 10 insiders.

Both sides are active: 4 purchases and 11 sales, from 4 insiders and 7 insiders respectively. No amount is published for 15 filings, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price.

The most recent open-market purchase was published on 13 July 2026, 97 days ago. The median gap between a trade and its publication by DART (FSS) is 7 days. The shorter that gap, the sooner other investors can see what insiders have done. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.

With 19 filings in twelve months, the company is more active than the median of 7 filings across the 2,648 companies we follow on the same exchange. Over the whole record (from 2024), the tally stands at 13 purchases and 11 sales.

Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.